Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation.

Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2 (BRCA1/2) -associated breast and ovarian cancers. We evaluated the efficacy and safety of olaparib in a spectrum of BRCA1/2-associated cancers.

Shapira-Frommer, Ronnie (author)
Schmutzler, Rita K (author)
Audeh, M William (author)
Friedlander, Michael (author)
Balmaña, Judith (author)
Mitchell, Gillian (author)
Fried, Georgeta (author)
Stemmer, Salomon M (author)
Hubert, Ayala (author)
Rosengarten, Ora (author)
Steiner, Mariana (author)
Loman, NiklasLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)onk-nlo (author)
Bowen, Karin (author)
Fielding, Anitra (author)
Domchek, Susan M (author)
TumörmikromiljöSektion I (creator_code:org_t)

By the author/editor: Kaufman, Bella; Shapira-Frommer, ...; Schmutzler, Rita ...; Audeh, M William; Friedlander, Mic ...; Balmaña, Judith; show more...; Mitchell, Gillia ...; Fried, Georgeta; Stemmer, Salomon ...; Hubert, Ayala; Rosengarten, Ora; Steiner, Mariana; Loman, Niklas; Bowen, Karin; Fielding, Anitra; Domchek, Susan M; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Cancer and Oncol ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.